周三盘中，医疗诊断公司NeoGenomics（股票代码：NEO）股价大跌5.24%，引发市场关注。
导致股价下跌的主要原因是华尔街知名分析机构Leerink Partners大幅下调了对NeoGenomics的评级和目标价。Leerink Partners将NeoGenomics的评级从"跑赢大盘"下调至"跑输大盘"，同时将目标价从25美元大幅下调至9美元，降幅高达64%。
Leerink Partners的这一举动反映出分析师对NeoGenomics未来业务前景的担忧。作为一家专注于癌症基因组检测的公司，NeoGenomics可能面临行业竞争加剧或需求放缓等挑战。这一评级下调可能会影响投资者对公司的信心，从而导致股价承压。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.